Physician profile
Douglas A Lipperd
NPI 1275596967
$1,370.28
in general payments reported to CMS, 2019-2025
18 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.90 · 2020: $11.56 · 2021: $31.00 · 2023: $158 · 2024: $33.29 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.82 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.48 | 2023-2025 | |
| Novo Nordisk INC | $173.11 | 2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $169.62 | 2025 | |
| Axsome Therapeutics, INC. | $100.09 | 2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.75 | 2025 | Caplyta |
| Astellas Pharma US INC | $94.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.49 | 2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $77.21 | 2020-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $64.14 | 2025 | Rexulti |
| Covidien Lp | $51.90 | 2019 | |
| Abbott Laboratories | $48.77 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $46.46 | 2025 | Zepbound, Mounjaro, Kisunla |
| Medtronic, INC. | $41.25 | 2023 | Bravo |
| Amgen INC. | $38.73 | 2025 | Otezla, Repatha |
| Beckman Coulter, INC. | $31.00 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.90 | 2024 | Quviviq |
| Exact Sciences Corporation | $16.69 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $10.69 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lipperd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.